Zolpidem Tartrate Market Size, Share & Trends Growth [2031]

Report Description

Zolpidem Tartrate Market Outlook 2031:

The Global Zolpidem Tartrate Market was estimated at USD 733.0 Million in 2022 and is anticipated to reach USD 968.6 Million by 2031, expanding at a CAGR of 3.2% during the forecast period.

Zolpidem tartrate is a sedative-hypnotic drug that is primarily used to treat insomnia. It belongs to a class of medications called nonbenzodiazepines, which have similar effects to benzodiazepines but with fewer side effects and lower potential for abuse.

Get Free Sample Report

Zolpidem works by enhancing the activity of a neurotransmitter called gamma-aminobutyric acid (GABA), which promotes sleep. It also reduces the activity of certain brain chemicals that keep us awake, such as histamine and acetylcholine. Zolpidem is available in various forms, including tablets, sublingual tablets, and extended-release tablets.

The recommended starting dose for adults is 5 mg for women and 5 mg or 10 mg for men, taken immediately before bedtime. The maximum recommended dose is 10 mg daily for women and 12.5 mg daily for men.

Macro-economic Factors

Demographic trends: The aging population is a major driver of the zolpidem tartrate market, as older adults are more prone to sleep disorders. According to the World Health Organization (WHO), the number of people aged 60 years and above is projected to more than double by 2050, which is expected to fuel the demand for zolpidem tartrate.

Economic development: The rising disposable income in emerging economies, such as India and China, is leading to an increase in healthcare spending, which is driving the demand for zolpidem tartrate. In addition, the growing prevalence of sleep disorders in these countries is further fuelling the market growth.

Technological advancements: The development of new drug delivery systems, such as sublingual tablets and extended-release formulations, is improving the efficacy and safety of zolpidem tartrate products, which is driving their adoption. In addition, the use of telemedicine and digital health technologies is making it easier for patients to access sleep disorder treatments, including zolpidem tartrate.

Competitive landscape: The increasing competition in the zolpidem tartrate market is driving consolidation and partnerships among key players. For instance, in 2019, Mylan NV announced its intention to acquire Upjohn Company LLC from Pfizer Inc for $7 billion, which includes a portfolio of branded and generic sleep disorder products, including zolpidem tartrate. This acquisition is expected to strengthen Mylan's position in the sleep disorder market and expand its product portfolio.

Zolpidem Tartrate Market Dynamics

Market Driver- Increasing prevalence of insomnia globally

Zolpidem tartrate market is the increasing prevalence of insomnia worldwide. According to a study published in the Journal of Sleep Research, insomnia affects approximately 30% of the general population, with higher prevalence rates observed in older adults and women.

This high prevalence rate has led to a significant increase in the demand for effective insomnia treatments, such as zolpidem tartrate.

Market Driver- Growing awareness and acceptance of nonbenzodiazepine sedative-hypnotics as a safer alternative to benzodiazepines

Growing awareness and acceptance of nonbenzodiazepine sedative-hypnotics as a safer alternative to benzodiazepines. Benzodiazepines have been associated with several adverse effects, including dependency, tolerance, and cognitive impairment, which has led to a shift towards nonbenzodiazepine sedative-hypnotics such as zolpidem tartrate.

Market Restraint- The availability of alternative drugs for treating insomnia.

The zolpidem tartrate market is the availability of alternative drugs for treating insomnia. Although zolpidem tartrate is a widely prescribed medication for insomnia, other non-benzodiazepine drugs such as eszopiclone, zaleplon, and ramelteon are also available in the market.

These drugs have similar efficacy and safety profiles as zolpidem tartrate but may have fewer side effects or better tolerability in some patients.

Additionally, the generic entry of zolpidem tartrate has also contributed to the market restraint. The patent for zolpidem tartrate expired in several countries, leading to the availability of generic versions at lower prices. This has increased competition in the market and put pressure on the branded manufacturers to reduce their prices or offer differentiated products to maintain their market share.

Market Opportunity- Rising demand for non-benzodiazepine sedatives

the rising demand for non-benzodiazepine sedatives is fueled by the potential side effects and addiction associated with benzodiazepines. Zolpidem tartrate offers a safer alternative with fewer side effects and lower potential for abuse.

According to the National Sleep Foundation, approximately 30% of adults in the US suffer from insomnia, and this figure is expected to rise with the aging population. This presents a significant market opportunity for zolpidem tartrate, as it is a non-benzodiazepine sedative that is effective in treating insomnia.

Scope of the Zolpidem Tartrate Market Report  

The report on the global zolpidem tartrate market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Zolpidem Tartrate Market Segmental Outlook

On the basis of dosage form/strength, the market is segmented into Tablet and Oral spray. Based on the Dosage form/strength, the Tablet segment held the largest market share of XX% in the zolpidem tartrate market in 2022, due to the tablets offer a precise dosage, making it easier for patients to adhere to their treatment regimen.

Additionally, tablets are more convenient than other dosage forms such as sublingual tablets or oral solutions, as they do not require special administration techniques and can be easily swallowed with water.

Get Free Sample Report

Based on Age group, the market is fragmented into adult (15 to 64 Years) and geriatric (> age 65 Years). The adult (15 to 64 Years) segment is held a 76.1% share of the market due to the higher prevalence of insomnia and sleep disorders in this age group.

According to a study by the National Sleep Foundation, approximately 30% of adults in the US suffer from insomnia, which is higher than the prevalence in children and the elderly. Additionally, as people age, they become more susceptible to sleep disorders, but the majority of cases still occur in the adult population.

In terms of the Sales channel, the market is fragmented into online pharmacy, retail pharmacy, and hospital pharmacy. The hospital pharmacy category held a XX% share of the market, during the forecast period.

The hospital pharmacy segment held the largest market share for zolpidem tartrate due to the high prevalence of insomnia and sleep disorders among hospitalized patients, as well as the increasing demand for non-benzodiazepine sedatives in the hospital setting due to their lower potential for abuse and fewer side effects compared to benzodiazepines.

Get Free Sample Report

Regional Outlook

Based on regions, the market is separated into namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The market in North America is projected to expand at a substantial CAGR during the forecast period. North America is expected to maintain its dominance in the global market during the forecast period, due to High prevalence of insomnia and sleep disorders in this region, which has led to a significant demand for sedative-hypnotic drugs like zolpidem tartrate and Well-established healthcare infrastructure and high healthcare expenditure in countries like the US and Canada, which has facilitated the adoption of advanced treatments for sleep disorders, further contributing to the market's dominance in North America, which is expected to fuel the growth of the region.

The market in Europe is expected to grow rapidly due to Increasing prevalence of insomnia and sleep disorders, according to a study by the European Sleep Research Society, approximately 40% of the European population suffers from sleep disorders, with insomnia being the most common.

This high prevalence of insomnia and sleep disorders presents a significant market opportunity for zolpidem tartrate, as it is an effective treatment for these conditions, which is expected to drive regional market growth.

Get Free Sample Report

Key Benefits for Industry Participants & Stakeholders

• In-depth Analysis of the global zolpidem tartrate market

• Historical, Current, and Projected Market Size in terms of Value

• Potential & Niche Segments and Regions Exhibiting Promising Growth Covered

• Industry Drivers, Restraints, and Opportunities Covered in the Study

• Recent Industry Trends and Developments

• Competitive Landscape & Strategies of Key Players

• Neutral Perspective on Global Zolpidem Tartrate Market Performance